Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

234 results about "Squamous Carcinomas" patented technology

Squamous cell carcinomas, also known as epidermoid carcinoma are a number of different types of cancer that result from squamous cells. These cells form the surface of the skin lining of hollow organs in the body and line the respiratory and digestive tracts.

Aloe exosome-like nano-vesicle capable of delaying skin photoaging as well as extraction method and application of aloe exosome-like nano-vesicle

PendingCN119286759AAvoid clearance effectsEasy to crossCosmetic preparationsToilet preparationsActinic keratosesSquamous cancer
The invention discloses aloe exosome-like nano-vesicles capable of delaying skin photoaging and an extraction method and application thereof, and belongs to the technical field of exosome-like nano-vesicle extraction. The extraction method of the aloe exosome-like nano-vesicles is designed and optimized, the yield of the aloe exosome-like nano-vesicles is obviously improved, and the extracted aloe exosome-like nano-vesicles can obviously delay skin photoaging and have an obvious improvement effect on skin fibroblast aging damage caused by ultraviolet radiation; a potential treatment means is provided for preventing or treating actinic keratosis caused by ultraviolet radiation and further possible squamous cell carcinoma.
Owner:JIANGSU UNIV +1

NSD3 degradation agent as well as preparation method and application thereof

ActiveCN119241502AOrganic active ingredientsOrganic chemistryDiseaseCarcinoma cell line
The invention discloses an NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of drug synthesis. The invention provides a compound as shown in a formula I. The compound has a good effect of degrading NSD3 protein in vitro, can inhibit proliferation of a squamous carcinoma cell line NCI-H1703, and is expected to serve as a new way for preventing and treating NSD3 related diseases. # imgabs0 #
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Composition for identifying oral squamous cell carcinoma based on saliva sample detection and application

The invention relates to a composition for identifying oral squamous cell carcinoma based on saliva sample detection and application, and belongs to the technical field of molecular biology. The composition provided by the invention is used for identifying the oral squamous cell carcinoma by detecting the expression of SNORD52 and / or SNORD65 in a saliva sample; the composition comprises a specific reverse transcription stem-loop primer, a specific detection forward primer, a specific detection probe and a universal reverse primer. According to the composition disclosed by the invention, the expression of SNORD52 and / or SNORD65 in a saliva sample is detected, and a binomial logistic regression model is combined to perform auxiliary judgment on the oral squamous cell carcinoma, so that the composition has relatively high sensitivity and specificity, and the identification accuracy of the oral squamous cell carcinoma can be improved. The invention further provides a kit containing the composition, a detection object of the kit is a saliva sample, and the kit has the advantages of being small in sample dosage, noninvasive in sampling, convenient, rapid, small in risk and the like.
Owner:长春科技学院

Engineering bionic nucleic acid nano-vesicle as well as preparation method and application thereof

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.
Owner:HARBIN MEDICAL UNIVERSITY

Micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and preparation method of micro-fluidic chip

The invention provides a micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and a preparation method thereof, and relates to the technical field of micro-fluidic chips, the chip comprises a four-layer structure: the first layer is a closed layer, the second layer is a culture solution / drug pool layer (containing a concentration gradient injection channel and a slow flow channel), the third layer is a matrix culture pool layer, and the fourth layer is a matrix culture pool layer. The fourth layer is a matrigel inflow layer (containing an S-shaped flow channel); the second layer and the third layer are integrally formed, and all the layers are connected through oxygen plasma welding; the problems that in the prior art, matrigel is prone to shifting, drug gradient regulation and control is poor, operation is tedious, and adaptability is insufficient are solved, the matrigel and organoids can be stably fixed, the drug concentration gradient can be precisely regulated and controlled, the nutrition supply efficiency is enhanced, the structural integration level and operation convenience are improved, and the application prospect is wide. The method is suitable for oral squamous cell carcinoma organoid culture, drug screening and tumor mechanism research.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY

Equipment, method and system for evaluating prognosis of cervical cancer, squamous carcinoma and adenocarcinoma and application of equipment, method and system

The invention provides equipment, a method and a system for evaluating prognosis of cervical cancer, squamous carcinoma and adenocarcinoma and application of the equipment, the method and the system, and belongs to the technical field of medical evaluation. Two biomarkers, namely adenylate kinase 4 and cavernous malformation 2 protein, for evaluating prognosis of cervical squamous cell carcinoma and adenocarcinoma are obtained through multivariate statistical analysis, difference screening, COX regression analysis and other biosignal analysis methods. Based on the biomarker, evaluation equipment, a computer execution method, a computer system and the like for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma are constructed, and the evaluation equipment, the computer execution method, the computer system and the like are used for accurately judging the prognosis condition of a cervical cancer patient.
Owner:ZHEJIANG CANCER HOSPITAL +1

Computer-aided drug screening method based on FBXO2 and PKM2

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.
Owner:CENT SOUTH UNIV

Engineering bionic nucleic acid nano diagnosis and treatment agent as well as preparation method and application thereof

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.
Owner:HARBIN MEDICAL UNIVERSITY

Application of neutrophil number level in prediction of tumor treatment effect

The invention discloses application of neutrophile granulocyte number level in prediction of tumor treatment effect. Through verification of the embodiment of the invention, the number level of neutrophils in blood of a tumor patient before treatment is closely associated with the curative effect of tumor treatment, especially OH2 treatment, and the applicable tumor adaptation diseases are common; comprising at least one of melanoma, esophageal cancer, right breast invasive ductal cancer, intestinal cancer, head and neck tumor, gastric cancer, ovarian cancer, biliary system tumor, left foot back squamous cell carcinoma, sarcoma and osteosarcoma, lung cancer, thymosquamous cell carcinoma and brain glioma. In the application disclosed by the invention, the threshold value of the number of neutrophils for predicting the tumor treatment effect is 3.5 * 10 < 9 > / L; the treatment is predicted to be effective when the number of sexual granulocytes in a tumor patient is below 3.5 * 109 / L before the tumor patient is treated, and the treatment is predicted to be ineffective or invalid when the number of sexual granulocytes in the tumor patient is higher than 3.5 * 109 / L. The application method is simple, low in cost and good in stability, and can become a potential prediction means for clinicians.
Owner:WUHAN BINHUI BIOTECH CO LTD

Antibody-Drug Conjugates Against EPH Receptor A5 (Epha5) for Treatment of Carcinoma

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.
Owner:MBRACE THERAPEUTICS INC

Methods of treatment for HPV malignancies

This invention relates to human papilloma virus (HPV) positive cancers such as HPV+ squamous cell carcinoma of the oropharynx (OPSCC). This invention further relates methods of determining treatment regimens, methods of stratifying prognosis from treatment of HPV positive cancers, methods of determining suitability for de-escalation of treatment of HPV positive cancers, and methods of treating HPV positive cancers.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Angiogenesis model and preparation method and application thereof

The invention discloses an angiogenesis model as well as a preparation method and application thereof. The method comprises the following steps: extracting from oral squamous cell carcinoma tissues to obtain cancer-related fibroblasts in the oral squamous cell carcinoma tissues; the human umbilical cord vein endothelial cells capable of stably expressing the m-Chryry red fluorescent protein are obtained; co-culturing cancer-related fibroblasts in the oral squamous cell carcinoma tissue and the human umbilical vein endothelial cells stably expressing the m-Chryry red fluorescent protein in an ultralow adsorption plate to obtain a co-cultured cell cluster; and adding a co-culture medium into the co-culture cell cluster system to obtain the angiogenesis model. The close contact type co-culture of the two cells is realized through close contact type co-culture of the two cells, and compared with a traditional indirect co-culture model for treating the cells by using a conditioned culture medium, the close contact type co-culture model disclosed by the invention can better simulate direct interaction between the cells in an in-vivo tumor microenvironment.
Owner:WUHAN UNIV

Application of receptor helper protein 6 and inhibitor thereof in preparation of medicine for treating oral squamous cell carcinoma

The invention discloses a receptor helper protein 6 and application of an inhibitor thereof in preparation of a medicine for treating oral squamous cell carcinoma. The invention discloses a receptor helper protein 6 as a novel ferroptosis inhibiting factor in OSCC cells, which is a key protein in a ferroptosis signal pathway and can be used as a drug target for overcoming the progress of oral squamous cell carcinoma. The knock-down of the REEP6 significantly inhibits the cell reproduction rate in the OSCC cell line, significantly promotes DNA damage in the OSCC cell line and significantly inhibits migration and invasion of the OSCC cell line, so that the inhibitor of the targeted receptor helper protein 6 can be applied as a drug for treating oral squamous cell carcinoma. The invention provides a new thought for diagnosing and preparing medicines for treating oral squamous cell carcinoma.
Owner:TAIHE HOSPITAL OF SHIYAN CITY (AFFILIATED HOSPITAL OF HUBEI UNIVERSITY OF MEDECINE)

Self-assembled polypeptide targeting mitochondria, preparation method and application of self-assembled polypeptide, self-assembled polypeptide microneedle patch and preparation method of self-assembled polypeptide microneedle patch

The invention belongs to the technical field of biological medicine, and provides self-assembled polypeptide targeting mitochondria, a preparation method and application of the self-assembled polypeptide, a self-assembled polypeptide microneedle patch and a preparation method of the self-assembled polypeptide microneedle patch. According to the self-assembly polypeptide of the targeted mitochondria, the amino acid sequence is GFFGKXRXKXRX, and X represents cyclohexyl alanine. A targeting peptide (Mito) sequence KXRXKXRX can recognize cell mitochondria in a targeting manner, a self-assembly sequence GFFG is introduced to an N terminal of the Mito sequence KXRXKXRX, and the targeting peptide sequence is endowed with a self-assembly capability, so that the self-assembly polypeptide can cause morphological function abnormality of mitochondria in tumor cells, the tumor cells are killed, and inhibition of the tumor cells is realized. The self-assembled polypeptide disclosed by the invention is applied to treatment of tumor cells through in-situ administration of the self-assembled polypeptide microneedle patch. Oral squamous cell carcinoma serves as a highly proliferated tumor cell, rapid proliferation of the oral squamous cell carcinoma needs a large amount of energy supply for mitochondria, and therefore attacking of the mitochondria can serve as an effective treatment target.
Owner:TIANJIN DENTAL HOSPITAL

Application of FOXA2 detection reagent in preparation of kit for diagnosis or differentiation degree evaluation and prognosis evaluation of head and neck squamous cell carcinoma

The invention discloses application of a reagent for detecting FOXA2 in preparation of a kit for diagnosis or differentiation degree evaluation and prognosis evaluation of head and neck squamous cell carcinoma. Wherein the reagent comprises a primer pair for amplifying the FOXA2; the primer pair comprises an upstream primer with a nucleotide sequence as shown in SEQ ID NO. 1 and a downstream primer with a nucleotide sequence as shown in SEQ ID NO. 2. By utilizing the kit, diagnosis, differentiation degree evaluation and prognosis evaluation of head and neck squamous cell carcinoma and oral squamous cell carcinoma can be effectively realized, and the kit is high in accuracy and good in repeatability.
Owner:PEKING UNIVERSITY SHENZHEN HOSPITAL

Antisense oligonucleotide for adjuvant therapy of oral squamous cell carcinoma and application of antisense oligonucleotide

The invention discloses antisense oligonucleotide for adjuvant therapy of oral squamous cell carcinoma and application of the antisense oligonucleotide. According to the invention, the rs737540 site and the mutant allele rs737540-T thereof are identified, so that the problem of lack of specific biomarkers and targeted therapy means in the prior art is solved. By designing the antisense oligonucleotide aiming at the rs737540 mutation site, selective splicing of TARDBP and EGFR exon 4 can be specifically blocked, and OSCC cell proliferation is inhibited. Besides, the EGFR targeted drug cetuximab is used in a combined manner, so that a stronger anti-cancer effect is realized, and the blank in the existing treatment means is filled. The core breakthrough of the technology is that genetic variation and targeted therapy are combined, and a new research thought and a clinical application prospect are provided for precise medicine of oral squamous cell carcinoma.
Owner:AFFILIATED STOMATOLOGICAL HOSPITAL OF NANJING MEDICAL UNIV

Method of evaluating pre-cancerous or cancerous lesions for oral cancer

A method of collecting oral mucosal cells from a patient and evaluating the oral mucosal cells for oral squamous cell carcinoma predisposition in the patient includes collecting a sample of chewing gum from a patient that had chewed the chewing gum for a minimum of about 5 minutes up to about 30 minutes. The chewing gum includes a molecular adherent targeted towards oral mucosal cells with oral squamous cell carcinoma predisposition. A polymerase chain reaction (PCR) is performed on a DNA template prepared from the chewed chewing gum using oligonucleotide primers that are selected to amplify nucleic acids that screen for genomic sequence variations seen in genes that are indicative of oral squamous cell carcinoma predisposition in the patient.
Owner:THOMAS K LEGGETT LLC

Treatment of squamous cell carcinoma

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.
Owner:PIKUR TERAPYUTIKS AG

Expiration marker combination for diagnosing oral squamous cell carcinoma as well as application and screening method thereof

The invention relates to the field of biomedicine, and discloses an expiration marker combination for diagnosing oral squamous cell carcinoma as well as application and a screening method of the expiration marker combination. Wherein the expiration marker combination comprises 29 oral expiration markers, a scoring model is constructed through the relative content of VOC signals of the expiration markers, the scoring model can be used for evaluating the oral squamous cell carcinoma risk of a patient, and the invention further discloses a screening method of the expiration marker combination. According to the screening method, a multi-algorithm feature union set strategy is adopted, the algorithm advantages of UTest, Boruta, LGBM, RF and the like are integrated, the limitation of a single algorithm is overcome, and the OSCC related expiration markers are recognized to the maximum extent. The core marker screening basis is clear, the PTR-TOF-MS detection process is standard, an interpretable verification mechanism is constructed, clinical popularization is facilitated, invasive biopsy dependence is reduced, diagnosis efficiency and patient compliance are improved, and important clinical and social values are achieved.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Application of CTLA-4, TIM-3 and LAG-3 as immune checkpoints in screening medicines for treating oral squamous cell carcinoma

The invention relates to the technical field of tumor molecular biology. The invention provides application of CTLA-4, TIM-3 and LAG-3 as immune checkpoints in screening of drugs for treating oral squamous cell carcinoma. According to the invention, expression differences of CTLA-4, TIM-3 and LAG-3 in oral squamous cell carcinoma tissues and normal tissues and correlation between expression of CTLA-4, TIM-3 and LAG-3 and CD8 + T cell infiltration are compared and analyzed, CTLA-4, TIM-3 and LAG-3 are screened as suitable immune checkpoints, and by inhibiting expression levels of CTLA-4, TIM-3 and LAG-3, activation and proliferation of T cells can be improved, positive regulation immune response can be increased, and the immunologic function of the oral squamous cell carcinoma is enhanced. Therefore, the oral squamous cell carcinoma treatment effect is improved.
Owner:SHENYANG FIFTH PEOPLES HOSPITAL

Detection marker and detection device for identifying primary and intra-wall metastasis of esophageal multifocal squamous carcinoma

The invention relates to a detection marker and a detection device for identifying primary and intrawall metastasis of esophageal multifocal squamous carcinoma, and belongs to the technical field of cancer detection markers. According to the invention, a detection site set composed of 20 genes is constructed, and the gene diagnosis purpose of distinguishing primary and intrawall metastasis of esophageal multi-lesion squamous cell carcinoma is realized by analyzing the difference of mutation types on lesions.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Method and system for measuring invasion depth of oral squamous cell carcinoma based on artificial intelligence

The invention relates to the technical field of image processing, and discloses an oral squamous cell carcinoma invasion depth measurement method and system based on artificial intelligence. The method comprises the steps of performing standardization processing on oral tissue slices through a three-dimensional preprocessing algorithm to obtain a tumor mask image and a confidence map, then performing multipoint sampling deployment of a virtual measurement agent on the tumor surface, detecting feasibility of an invasion path by using a tissue resistance model, performing multi-branch feature extraction and deep regression calculation through an OSCC-DepthNet network, and finally obtaining the tumor mask image and the confidence map through the OSCC-DepthNet network. And obtaining an invasion path and a depth value of each agent, fusing multi-agent measurement results by adopting a confidence weighting algorithm, and outputting an oral squamous cell carcinoma invasion depth value and an uncertainty estimation value. The technical problems that an existing oral squamous cell carcinoma invasion depth measurement method is insufficient in three-dimensional space measurement capacity, too high in calculation complexity, poor in real-time performance and lack of an effective uncertainty quantification mechanism are solved.
Owner:FOSHAN DENTAL HOSPITAL

Application of LncRNA GSEC in preparation of medicine for treating oral squamous cell carcinoma

The invention discloses application of LncRNA GSEC in preparation of a medicine for treating oral squamous cell carcinoma, and relates to the technical field of biological medicine. The nucleotide sequence of the LncRNA GSEC is shown as SEQ ID NO: 1, the medicine contains an active component capable of inhibiting expression or functions of the LncRNA GSEC, the active component is one or more of siRNA, shRNA or a small-molecule inhibitor, and the medicine is used for inhibiting proliferation, migration and / or invasion of OSCC cells and / or inducing cell apoptosis. The specific high expression of the LncRNA GSEC in oral squamous cell carcinoma tissues and cells is disclosed for the first time, and the expression level of the LncRNA GSEC is remarkably and positively correlated with adverse clinical parameters such as tumor T staging and lymph node metastasis, so that the LncRNA GSEC is proved to serve as a novel molecular target with clinical application potential.
Owner:AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIV (INNER MONGOLIA AUTONOMOUS REGION CARDIOVASCULAR INST) +1

Application of lactobacillus muricatum in preparation of medicine for treating oral cancer

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.
Owner:STOMATOLOGICAL HOSPITAL OF CHONGQING MEDICAL UNIV

N-(1h-indol-2-yl)methyl)-4-ethynyl-picolinamide derivatives as EGFR inhibitors for the treatment of cancer

Provided herein are compounds of formula A having an amide-based backbone that is connected to multiple ring structures, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions thereof, and the compounds for use in methods of medical treatment as selective allosteric inhibitors of EGFR mutants, for the treatment of cancer, such as e.g. lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, non-small cell lung cancer (NSCLC), or cancer with brain metastasis, wherein the cancer is characterized as having at least one EGFR mutation selected from L858R, T790M, and C797S.
Owner:ALLORION THERAPEUTICS INC +1

Cancer-associated fibroblast cell line, method for constructing the same and use thereof

PendingCN122278766Aclear sourcehigh puritySquamous CarcinomasFibroblast cell line
This invention relates to the interdisciplinary field of cell biology, experimental oncology, and translational medicine, specifically to a cancer-associated fibroblast cell line, its construction method, and its applications. This invention fills the research gap in mouse-derived oral squamous cell carcinoma-associated fibroblast cell line models and provides a method for constructing such a cell line. Through the inverted adherent culture and enzymatic digestion methods of this invention, a mouse-derived oral squamous cell carcinoma-associated fibroblast cell line with a clear origin, high purity, and long-term phenotypic and functional stability can be obtained. This allows for the establishment of a cryopreservable and resuscitable mouse oral squamous cell carcinoma-associated fibroblast cell bank, providing technical support for research related to the tumor microenvironment and immunotherapy.
Owner:WEST CHINA STOMATOLOGICAL HOSPITAL OF SICHUAN UNIV

Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector

The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof. The PD-L1 binding molecules and pharmaceutical compositions thereof have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and / or immune cells), for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutics for treating or slowing the progression of cancer (e.g., non-small cell lung cancer or squamous cell carcinoma of the head and neck). The present disclosure also relates to clinical methods for use of the disclosed PD-L1 binding molecules for treating a subject in need thereof.
Owner:MOLECULAR TEMPLATES INC

Preparation method and application of nanoparticles for treating oral squamous cell carcinoma

PendingCN119326911APowder deliveryBacteria material medical ingredientsMultifunctional nanoparticlesSquamous Carcinomas
The invention discloses a preparation method and application of nano particles for treating oral squamous cell carcinoma, the multifunctional nano particles take dendritic macroporous mesoporous silica as a template, titanium dioxide continues to grow on the surface of the template, and then the obtained mesoporous titanium dioxide is subjected to quaternary ammonium functionalization to obtain the nano particles for treating oral squamous cell carcinoma. And finally, carrying porphyromonas gingivalis cell walls with multiple functions through electrostatic interaction. The nano particles have sonodynamic and chemical dynamic therapy performance, hydrogen peroxide can be catalyzed to generate oxygen, the oxygen and glutathione are subjected to an oxidation-reduction reaction, and carried porphyromonas gingivalis cell walls can activate anti-tumor immune response. The nanoparticles can be used for treating oral squamous cell carcinoma in combination with sonodynamic, chemical dynamic and bacterial immunity under ultrasonic excitation, and recurrence and metastasis of tumors are effectively inhibited through combination of multiple strategies. The method is reasonable in design and simple to operate, can improve the treatment effect of oral squamous cell carcinoma, and has important clinical significance.
Owner:SICHUAN INNOVATION RES INST OF TIANJIN UNIV +4

Campylobacter for treating oral squamous cell carcinoma and application thereof

The application discloses a Campylobacter for treating oral squamous cell carcinoma and application thereof. It is found by the application that a Campylobacter showae strain has significant anti-tumor activity on a mouse model of oral squamous cell carcinoma, can significantly inhibit tumor growth, and promote the formation of tertiary lymphoid structures in oral squamous cell carcinoma. Therefore, the Campylobacter showae strain and a composition thereof can be used for preparing products for preventing, treating, adjuvant treating or prognosis nursing oral squamous cell carcinoma, and provide a new microbial intervention strategy for oral squamous cell carcinoma and related immunotherapy.
Owner:Furong Laboratory +1